NT-0249 is under clinical development by NodThera and currently in Phase I for Chronic Inflammation. According to GlobalData, Phase I drugs for Chronic Inflammation does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NT-0249 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NT-0249 overview
NT-0249 is under development for the treatment of peripheral chronic inflammatory disease. The drug candidate acts by targeting NLRP3 inflammasome and is administered by oral route in the form of capsule.
NodThera overview
NodThera, a subsidiary of NodThera Ltd, is a biotechnology company that discovers and develops treatments for chronic inflammation. It is investigating its lead product candidate NT-0796 against peripheral and neuroinflammatory diseases. The company is also evaluating NT-0249, a peripherally restricted NLRP3 inflammasome inhibitor to develop a low-dose therapy addressing chronic inflammatory diseases of the body. NodThera’s approach focuses on delivering advances in potency, tissue and brain penetration and chemical structural diversity. It operates with additional offices in Seattle, the US, and Cambridge, the UK. NodThera is headquartered in Lexington, Massachusetts, the US.
For a complete picture of NT-0249’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.